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Background and Aim 
Functional dyspepsia (FD) is a common disorder of gut-brain interaction with incompletely 
understood pathophysiology. Consequently, heterogenous expert opinions on diagnostic 
tests and assessment of treatment efficacies exist.  So far, no consensus about the most 
relevant diagnostic and outcome tool has been reached. In this study we aimed to analyze the 
significance of a combined lactulose hydrogen breath test and liquid meal (LHBT), yet 
representing a standardized test in IBS, in FD. 
 
Methods 
We analyzed data of 146 FD, 204 IBS patients and 50 HV. All patients underwent LHBT with a 
meal-drink consisting of 30g Lactulose and 400ml Ensure®. Effect of abdominal symptom 
generation in FD/IBS compared to HV was assessed on a patient-reported Likert-scale.  
 
Results 
There was a significant difference between FD/IBS-patients and HV in LHBT induced 
abdominal pain (OR 246.9, 95% CI 26.6-2290.7 / OR 161.2, 95% CI 16.9-1534.8), abdominal 
bloating (OR 384.8, 95% CI 92.9-2135.4 / OR 524.1, 95% CI 114.7-3432.3), borborygmi (OR 9.9, 
95% CI 2.2-46.9 / OR 17.7, 95% CI 4.7-67.4), nausea only in FD (OR 174.4, 95% CI 15.5-5375.5) 
and diarrhea in IBS-only (OR 25.8, 95% CI 2.0-7012.6). Hydrogen production was not 
significantly different in FD/IBS and HV.  
 
Conclusions 
In this study we demonstrated significant differences in postprandial symptom generation in 
FD and IBS compared to HV after LHBT. This does not only allow us to discriminate FD/IBS from 
HV but may also represent a diagnostic and monitoring tool for FD/IBS in the future, including 
monitoring of treatment effects.  
 
Keywords: Functional disorders, dyspepsia, gastric motility and sensation, nutrient transport and 
metabolism, clinical intestinal disorders 
 Introduction: 
Functional dyspepsia (FD) is a highly prevalent disorder of gut-brain interaction (FGID) with 
incompletely understood pathophysiology. As a consequence, heterogenous expert opinions 
on diagnostic tests and assessment of treatment efficacies exist.  So far, no general consensus 
about the most relevant diagnostic and outcome tools has been reached.  
FD is defined according to Rome IV criteria (1) as bothersome postprandial fullness and/or 
bothersome early satiation and/or bothersome epigastric pain and/or bothersome epigastric 
burning in combination with no evidence of structural disease that is likely to explain the 
symptoms. Additionally, FD patients often report symptoms like nausea and upper abdominal 
bloating after food intake (2, 3). Clinical and preclinical tests in FD patients range from gastric 
emptying/accommodation studies to Helicobacter pylori, duodenal biopsies, 
environmental/nutritional analyses, psychological questionnaires as well as hydrogen tests. 
Even though hydrogen breath tests in patients with FGIDs have been discussed controversially 
in the past years, they are stated to be useful in the diagnosis of carbohydrate maldigestion 
syndromes and the assessment of conditions associated with bloating as stated in the recently 
released North American Consensus on Breath Testing in gastrointestinal (GI) disorders (4). 
Unfortunately, wide heterogeneity in test execution and analysis has hindered comparisons 
and acceptance of results. The clinical significance of test results and therapeutic 
consequences often remain ambiguous. Also, frequency of breath sampling, test duration, 
dose and choice of test substance vary between institutions.  
Among multiple studies analyzing lactulose hydrogen breath tests, Le Neve et al. (5) 
demonstrated differences in symptom response following a combined lactulose nutrient 
breath test (LHBT) between patients with irritable bowel syndrome (IBS) and healthy controls. 
Using this test made up of a standardized liquid meal in combination with fermentable 
carbohydrate lactulose, Pohl et al. recently showed differences in postprandial symptom 
generation in patients with IBS versus patients with combined IBS-FD and healthy controls (6). 
As a consequence of above mentioned findings, we hypothesized that not only IBS or IBS-FD 
but also FD-only patients may be discriminated from healthy volunteers (HV) based on 
abdominal symptoms and hydrogen values. The aim of this study was therefore to 
discriminate FD patients from HV based on the LHBT originally developed for IBS patients.  
 Methods 
Design and study population 
We prospectively collected data of 50 HV with signed informed consent, which responded to 
an advertisement. Inclusion criteria were age between 18-60 years, no antibiotic treatment 4 
weeks prior to LHBT and no known gastrointestinal disorder (including FD and IBS) as well as 
lack of prior abdominal surgery.  Data of HV were collected by physicians interviewing HV.   
Between January 2015 and November 2017 data of 146 consecutive patients with FD (FD-only 
and FD-IBS mixed type) and 204 patients with IBS (IBS-only) who underwent LHBT as part of 
their routine work-up in our laboratory were analyzed. Most of the patients were part of our 
specialized functional gastrointestinal ambulatory clinic and only a few patients were referred 
from outside. All patients had prior endoscopy excluding structural disorders as well as H. 
pylori infection or GI ulcera.  Inclusion criteria were general informed consent, age older than 
18 and FD and/or IBS diagnosed according to Rome IV, respectively Rome III criteria (1, 7).   
 
Lactulose hydrogen breath testing 
HV, FD and IBS patients were advised to a fasting period of at least 6-8 hours (incl. smoking 
and chewing gum) before LHBT in line with recommendations of the North American Breath 
Testing Consensus (4). LHBT was performed with Breathalyzer-HydroCheck (NEOMED 
Medizintechnik GmbH) after mouth rinse with 15-20 ml Drossadin Solution 0.1% for 30 
seconds. Two baseline hydrogen measurements were performed and expressed in parts per 
million (ppm) and five baseline abdominal symptoms (nausea, abdominal pain, borborygmi, 
abdominal bloating and diarrhea) were recorded before ingestion of 400ml Ensure® (600 kcal, 
20g fat, 81g carbohydrate, 25g protein) and 30g Lactulose. Hydrogen values and abdominal 
symptoms were collected in 10min intervals for a total of 180 minutes. Abdominal symptoms 
were assessed on a 5-point Likert scale from 0 to 4 with 0 corresponding to no symptom and 
4 resembling very strong symptoms. 
 
Statistical analysis 
Data of continuous variables with Gaussian distribution are presented as means ± standard 
deviation (SD) and as median and range in case of other than normal distribution. Kruskal-
Wallis-, t-test, ANOVA, Chi-squared and fisher exact test were used to compare demographics 
between healthy volunteers and FD patients. Mixed-effects models were used to assess group 
effects using the function “lme” from the R package ”nlme” for hydrogen and “glmer” from 
the R package “lme4” for abdominal symptoms. Further, a nonparametric analysis of the 
longitudinal data was performed testing the relative effect of factor group using the function 
“f1.ld.f1” and the ANOVA-type statistic of the R package “nparLD”. Age and sex were entered 
into multivariable models as covariates of no interest.  A p-value < 0.05 was considered 
statistically significant.  
For the ROC, an equally sized test and training data set were created, drawing a random 
sample from the HV and the respective patient group (all patients, FD, FD-only, FD-IBS, IBS-
only). After fitting a model with the training data set, the model parameters were used to 
predict the status (HV or patient) with the test data set. Subsequently, a ROC-GLM curve and 
a confusion matrix were produced. 
Statistical analyses were performed with R Version 3.2.0 (R Foundation for Statistical 
Computing, Vienna, Austria). Zurich Ethical Committee (BASEC-Nr. 2016-01887) approved the 
study. 
 
Results 
Patient characteristics 
Of 350 patients 34 had FD-only, 112 had overlap FD-IBS and 204 patients suffered from IBS-
only. The majority of patients were female (71.9% vs. 28.1%), which was also true in both 
subgroups (FD-only 24 females [70.6%], FD-IBS subgroup 81 females [72.3%], IBS-only 141 
females [69.1%]). In HV the female to male ratio was 33 to 17 (66.0% vs. 34.0%) in accordance 
with the general gender distribution of this entity. Median age in FD was 34 years (ys) (range 
18-75ys), in FD-only 37 (range 21-71ys), in FD-IBS 34 (range 18-75ys), in IBS-only 36 (range 18-
77ys) and in HV 25 (range 18-58ys) (p<0.001).  
 Abdominal Symptoms 
Group effect 
There was a significant difference between patients with FD and HV in LHBT induced nausea 
(OR 174.4, 95% CI 15.5-5375.5), abdominal pain (OR 246.9, 95% CI 26.6-2290.7), abdominal 
bloating (OR 384.8, 95% CI 92.9-2135.4) and borborygmi (OR 9.9, 95% CI 2.2-46.9). Effects 
remained significant after adjustment for age and gender. Only the occurrence of diarrhea did 
not significantly differ between the two groups (OR 12.3, 95% CI 0.2-970.9) figure 1-5 
In the subgroup of FD-only compared to HV, there was a significant difference in LHBT induced 
nausea (OR 171.5, 95% CI 28.1-2203.5), abdominal bloating (OR 175.3, 95% CI 28.4-1719.9) 
and abdominal pain (OR 84.1, 95% CI 0.8-8845.6) figure 1-5. Borborygmi (OR 3.6, 95% CI 0.3-
33-4) and diarrhea showed no significance in postprandial symptom generation (OR 6.2, 95% 
CI 0.0-1126.2). All results were adjusted for age and gender. 
In the FD-IBS subgroup there was a significant difference in LHBT induced nausea (OR 37.6, 
95% CI 1.9-34019.4), abdominal bloating (OR 527.0 95% CI 117.6-3281.4), abdominal pain (OR 
286.1, 95% CI 31.9-2564.6) and borborygmi (OR 13.3, 95% CI 3.2-61.6) compared to HV figure 
1-5.  A significant effect on diarrhea was not found (OR 14.8, 95% CI 0.2-1124.7). Again, results 
remained unchanged after adjustment for age and gender.  
In the subgroup of IBS-only compared to HV there was a significant difference in LHBT induced 
abdominal pain (OR 161.2, 95% CI 16.9-1534.8), abdominal bloating (OR 524.1, 95% CI 114.7-
3432.3), borborygmi (OR 17.7, 95% CI 4.7-67.4) and diarrhea (OR 25.8, 95% CI 2.0-7012.6). No 
significant difference was seen in nausea (OR 15.5, 95% CI 1.0-16267.8). 
 
 
Time effect 
There was a significant effect of time in FD-only patients on nausea (OR 0.87, 95% CI 0.82-
0.92), borborygmi (OR 1.14, 95% CI 1.07-1.23), diarrhea (OR 1.28, 95% CI 1.10-1.55), but not 
on abdominal bloating (OR 1.04, 95% CI 0.99-1.09) and pain (OR 0.98, 95% CI 0.93-1.04). 
The time effect in FD-IBS patients was significant for nausea (OR 0.87, 95% CI 0.83-0.90), 
abdominal bloating (OR 1.09 95% CI 1.06-1.13), borborygmi (OR 1.11, 95% CI 1.07-1.15), 
diarrhea (OR1.16, 95% CI 1.09-1.24), but not for abdominal pain (OR 1.03, 95% CI 1.00-1.07).  
In IBS-only patients there was a significant effect of time on abdominal bloating (OR 1.13, 95% 
CI 1.11-1.16), on diarrhea (OR 1.26, 95% CI 1.21-1.32), borborymgi (OR 1.10, 95% CI 1.07-1.13), 
in nausea (OR 0.86, 95% CI 0.83-0.89) and in abdominal pain (OR 1.08, 95% CI 1.05-1.10). 
Hydrogen Values  
Group effect  
FD patients averaged 2.3ppm higher hydrogen values (95% CI (-2.7) – 7.2) than HV, without 
reaching significance. The effect of FD-only and FD-IBS subgroups on hydrogen values was 
neither significant considering the whole period (10-180 minutes) with FD-only patients 
having 0.2ppm and FD-IBS patients having 2.9ppm higher hydrogen values compared to HV 
(95%CI (-6.1)-6.5 resp. (-2.4)-8.2). IBS patients had an average of 3.59ppm higher hydrogen 
values (95% CI (-1.36) – 8.55) than HV.  figure 6 
After adjusting for age and gender the difference in hydrogen values between FD/IBS and HV 
remained insignificant (2.4, 95% CI (-2.9)-7.6 / 2.65, 95% CI (-1.49)-7.79).  
 
Discrimination between FD patients and HV 
There was a good discriminatory capacity for FD and IBS-only as compared to HV (AUC = 0.82 
resp. AUC = 0.91) and a high predictive capacity for FD (sensitivity = 0.72, specificity = 0.84) 
based on abdominal symptoms and hydrogen values. In FD-only patients AUC was 0.83 
(sensitivity = 0.69, specificity = 0.88), in FD-IBS 0.84 (sensitivity = 0.84, specificity = 0.80) and 
in IBS-only sensitivity was 0.91 and specificity = 0.56.  figure 7-10 
Discussion 
This study demonstrates a significant difference in LHBT induced abdominal symptoms in 
patients with FD and IBS compared to HV. In specific, abdominal pain, bloating, borborygmi 
and nausea were significantly more often induced in FD patients than HV, with a test that was 
originally developed to discriminate IBS patients from HV (8). It is currently believed that 
visceral hypersensitivity of the upper GI tract is partly accountable for these findings in FD 
patients. (9). In a recent review, the impaired somatosensation in FD patients was attributed 
to neuro-imaging anomalies in the somatosensory cortex, the cognitive and the affective 
regions. These, in turn, were assumed to be involved in a dysfunctional gut-brain axis thereby 
leading to altered symptom perception in FD patients (10). In accordance to this, Farre et al. 
demonstrated significantly lower postprandial discomfort thresholds during balloon 
distention in FD patients compared to controls and attributed this to visceral hypersensitivity 
(11). However, balloon distention tests are neither practical nor well tolerated in patients nor 
widely available and constitute an assessment reserved for research or highly specialized 
centers. This underlines the importance of analyzing responses of standardized food-
provocation testing in the large patient group with disorders of gut-brain interaction. A 
previous study by Woodtli et al. (12)  addressing FD in combination with food intake showed 
induction of nausea and bloating after lipid but not saline infusion in FD patients. These 
findings go in line with our results showing induction of bloating and nausea after ingestion of 
our liquid lipid-containing test meal in FD patients. It leads to the assumption of duodenal 
hypersensitivity to lipids and consecutive symptom generation in FD patients but not HV. It 
also supports the hypothesis of the test meal originally developed for IBS diagnostics 
representing an adequate composition or at least containing important ingredients for FD 
diagnostics, as well. Consequently, the advantage of the studied test method, as compared to 
previous FD studies is, that the same substances and setting can as well be used for IBS 
patients. In contrast to other nutrient studies in FD patients our test uses a significantly higher 
caloric load (13). This might explain the clear discrimination between FD, IBS and HV based on 
abdominal symptoms. Another advantage is, that no detailed questionnaire needs to be 
completed to discriminate between FD/IBS patients and HV as it has been the case for 
previous patient-reported outcome measures (PROM) (14-17). The test also meets the FDA 
criterion of a PROM representing a direct report from the patient without its interpretation 
by a clinician. In the past, tests with investigator-administered instruments were described to 
be limited as clinician’s interpretation often underestimates symptom severity (18, 19).  
A limitation of our study is that our symptom assessment included only nausea, abdominal 
bloating and abdominal pain as typical FD symptoms. We did not document symptoms of early 
satiation, postprandial fullness or belching. However, the few symptoms were sufficient to 
discriminate between FD and HV with high specificity. 
In contrast to the significant difference in abdominal symptoms, no significant hydrogen 
difference was seen in FD/IBS as compared to HV. However, hydrogen values tended to be 
higher in FD/IBS patients compared to HV between 30-100min figure 6. A possible explanation 
for this might be a higher mucosal bacterial load in the proximal small intestine. This 
hypothesis would be consistent with the finding of Zhong et al. who showed a positive 
correlation between duodenal mucosal bacterial load and symptom severity response to a 
standardized meal in FD patients (20, 21), including increase in total duodenal bacterial load. 
Supporting the involvement of the microbiome in FD patients is the fact that a large 
proportion of FD patients in the underlying cohort suffered from FD-IBS overlap. A higher 
prevalence of small intestine bacterial overgrowth (SIBO) is known in IBS patients and 
therefore likely in IBS-FD patients, too (22). However, the IBS influence only partially explains 
this finding since also patients with isolated FD tended to have higher hydrogen values figure 
6. Costa et al. postulated that also FD patients could have a higher prevalence of SIBO 
compared to HV (23) based on higher hydrogen measurements after lactulose ingestion.  
If the LHBT does not only allow to discriminate between FD/IBS and HV but also predicts 
response to different FD or IBS therapies has not been evaluated yet. As lactulose technically 
belongs to the FODMAP group (fermentable oligo-, di-, monosaccharides and polyols), one 
could assume that FD and IBS patients with increased abdominal symptoms induced by LHBT 
might respond better to a diet low in FODMAPs. However, lactulose may only represent one 
FODMAP-subgroup. It has yet to be shown if other FODMAP-groups induce similar symptom 
patterns and potentially predict treatment response. To verify this, prospective studies are 
needed.  
In conclusion, the underlying analysis demonstrated significant differences in abdominal 
symptoms induced by LHBT in FD patients compared to HV, suggesting a practical and safe 
method to not only distinguish between IBS and HV as described by Le Neve et al. but also 
between FD and HV. Additionally, despite big efforts during the last years no developed PROM 
is currently considered appropriate in FD patients (17). Considering this, we think, that the 
LHBT as an instrument including subjective as well as objective measure represents a useful 
tool for diagnostic work-up and to monitor and predict the therapeutic progress in FD patients 
in the future.  
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Figure 1: mean level of abdominal pain in patients with FD/IBS and HV over time. HC: healthy 
controls, FD: patients with functional dyspepsia, IBS only: patients with only irritable bowel 
syndrome, FD only: patients with only functional dyspepsia, FD-IBS overlap: patients with functional 
dyspepsia and irritable bowel syndrome overlap 
  
Figure 2: mean level of abdominal bloating in patients with FD/IBS and HV over time. HC: healthy 
controls, FD: patients with functional dyspepsia, IBS only: patients with only irritable bowel 
syndrome, FD only: patients with only functional dyspepsia, FD-IBS overlap: patients with functional 
dyspepsia and irritable bowel syndrome overlap 
 
  
Figure 3: mean level of borborygmi in patients with FD/IBS and HV over time. HC: healthy controls, 
FD: patients with functional dyspepsia, IBS only: patients with only irritable bowel syndrome, FD only: 
patients with only functional dyspepsia, FD-IBS overlap: patients with functional dyspepsia and 
irritable bowel syndrome overlap 
 
 
  
Figure 4: mean level of nausea in patients with FD/IBS and HV over time. HC: healthy controls, FD: 
patients with functional dyspepsia, IBS only: patients with only irritable bowel syndrome, FD only: 
patients with only functional dyspepsia, FD-IBS overlap: patients with functional dyspepsia and 
irritable bowel syndrome overlap 
 
  
Figure 5: mean level of diarrhea in patients with FD/IBS and HV over time. HC: healthy controls, FD: 
patients with functional dyspepsia, IBS only: patients with only irritable bowel syndrome, FD only: 
patients with only functional dyspepsia, FD-IBS overlap: patients with functional dyspepsia and 
irritable bowel syndrome overlap 
 
  
Figure 6: mean level of hydrogen in patients with FD/IBS and HV over time. HC: healthy controls, FD: 
patients with functional dyspepsia, IBS only: patients with only irritable bowel syndrome, FD only: 
patients with only functional dyspepsia, FD-IBS overlap: patients with functional dyspepsia and 
irritable bowel syndrome overlap 
  
Figure 7: Receiver Operating Characteristic Curve (ROC) for the median of abdominal symptoms and 
hydrogen values in functional dyspepsia (FD) patients compared to healthy controls (HC) 
  
Figure 8: Receiver Operating Characteristic Curve (ROC) for the median of abdominal symptoms and 
hydrogen values in functional dyspepsia (FD-only) patients compared to healthy controls (HC) 
  
Figure 9: Receiver Operating Characteristic Curve (ROC) for the median of abdominal symptoms and 
hydrogen values in mixed type functional dyspepsia and irritable bowel syndrome  (FD-IBS) patients 
compared to healthy controls (HC) 
  
Figure 10: Receiver Operating Characteristic Curve (ROC) for the median of abdominal symptoms and 
hydrogen values in irritable bowel syndrome  (IBS-only) patients compared to healthy controls (HC) 
 
